The FDA tasks industry with compiling and reporting medical device complications and failures. However, the current postmarket surveillance system has not been able to detect a disturbing number of device failures. For example:
• The ATJR was the first to recognize the excessive revision rate of metal-on-metal hip replacements and is primarily responsible for the withdrawal of MoMHR from the global market and for the diminished popularity of MoMHSR. 1 • The delayed recognition of upstaging of uterine cancers with "minimally invasive" morcellators. • The spread of carbapenem-resistant Enterobacteriaceae (CRE) due to design-related problems rendering fiberoptic duodenal endoscopes difficult to sterilize.
The above points to the need for rigorous premarket testing and postmarket follow-up on high-risk medical devices.
To be effective, medical device adverse event reporting must be transparent, universal, and not dependent on industry. In the U.S. Healthcare System, reporting of medical device-related complications has been sporadic and confounded by conflict of interest. Little useful information from the FDA's medical device reports survives redaction, substantially limiting the usefulness of the publically assessable Manufacturer and User Facility Device Experience database (MAUDE). The MAUDE has been unable to achieve its intended function as a leading indicator of an underperforming or otherwise dangerous medical device.
The lack of effective FDA regulatory oversight has fueled litigation, which by default seems to be the only, albeit inefficient, force promoting safe medical device development in the United States.
The tort system is unjust, inefficient, and ineffective. In recent litigation, Johnson and Johnson paid a $500 million dollar verdict to just 5 plaintiffs who were injured with the Pinnacle metalon-metal hip implant. 7 Approximately 350 million was awarded in punitive damages. DePuy's cost to settle 12,000 ASR claims is estimated to be in excess of $4 billion. 8 Only 1 in 5 patients with ASR hips are within this litigation cohort, yet 4 of 5 are likely to require costly, complication prone, premature revision surgery related to metallosis.
Between MoMHR, MoMHSR, and the hips prone to MACC, it is likely a million Americans will undergo premature revision surgery because of metallosis complications. Assuming a medical cost of $50,000 per revised hip and a 30% surplus 10-year revision rate, the American medical cost of remediation of hip metallosis complications will be on the order of $50 billion dollars. Given the present rate of litigation, its expense, and assuming that a third of the awards will be dedicated to medical expense, $45 billion of the medical remediation cost will be borne by the public. The lion's share will fall to Medicare, given the age of patients by the time that revision surgery is indicated.
The 21st Century Cures Act is currently being debated in the legislature. Many patient advocates had hoped it would fix the 510 K "loophole" but instead it further weakens safeguards for FIGURE 2. Adverse reactions to metallic debris from mechanically assisted crevice corrosion. Left-A recalled Stryker Rejuvenate, note corrosion of the female bores for the chrome-cobalt head and the titanium alloy stem and at the male ends of the chrome-cobalt neck. Right-A nonrecalled Zimmer ML Taper stem with a chrome-cobalt ball revised for symptomatic hip pseudotumor, hypercobaltemia, and neurocobaltism. patient safety by reducing the level of evidence necessary for a device to obtain a PMA designation. It also fails to reform the 510 (k) process. 9 Premarket approval status also grants devices near immunity to civil litigation. However, litigation can proceed on issues surrounding the integrity of the underlying research, which was presented to the FDA.
The FDA's premarket approval processes and postmarket surveillance mechanisms are systematically flawed and have resulted in incalculable suffering at great public expense. The 21st Century Cures Act places the fox in the coop, and it needs to be amended to strengthen patient protection or be discarded.
